Safety and Efficacy of Adding Intravenous N-acetyl Cysteine in Colon Surgeries
Primary Purpose
Systemic Inflammatory Response Syndrome
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
N Acetyl L Cysteine
dextrose 5%
Sponsored by
About this trial
This is an interventional prevention trial for Systemic Inflammatory Response Syndrome
Eligibility Criteria
Inclusion Criteria:
- need for ICU admission after colonic surgery
- requirement of total parenteral nutrition for at least 5 days due to failure of or contraindication for enteral nutrition
- signing a written informed consent.
Exclusion Criteria:
- patients with persistent hemodynamic instability (systolic blood pressure <80 mm Hg), renal impairment, hepatic insufficiency, severe or uncontrolled sepsis, persistent metabolic acidosis, head trauma,and heart failure
- any sensitivity to components of L-alanyl L-glutamine (Dipeptiven®, Fresenius Kabi, Germany) or N acetyl cysteine
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
N acetylcysteine group
placebo group
Arm Description
N Acetyl L Cysteine IV bolus (100 mg/kg dissolved in dextrose5%) infused over 15 minutes, followed by continuous infusion of 50mg/kg/day dissolved in dextrose 5% starting 1hr before induction of anesthesia, and continued for 48 hours after operation
received equal volume of dextrose 5% administrated at the same rate and duration as in the study group as a placebo
Outcomes
Primary Outcome Measures
assessing a change in the level of tumor necrosis factor alpha (TNF alpha) as ant-inflammatory marker reflecting n acetyl cysteine efficacy
TNF alpha was measured using ELISA technique
assessing a change in the level of malondialdehyde as antioxidant marker in the venous blood sample reflecting n acetyl cysteine efficacy
malondialdehyde was measured using colorimetric method for assay
Secondary Outcome Measures
measuring safety of N acetyl cysteine (adverse effects)
recording any adverse effects that may appear
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03589495
Brief Title
Safety and Efficacy of Adding Intravenous N-acetyl Cysteine in Colon Surgeries
Official Title
Safety and Efficacy of Adding Intravenous N-acetyl Cysteine to Parenteral L-alanyl L-glutamine in Hospitalized Patients Undergoing Colon Surgeries
Study Type
Interventional
2. Study Status
Record Verification Date
July 2018
Overall Recruitment Status
Completed
Study Start Date
July 30, 2015 (Actual)
Primary Completion Date
October 15, 2016 (Actual)
Study Completion Date
October 15, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ain Shams University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
5. Study Description
Brief Summary
The use of antioxidant agents in the prevention or decreasing the severity of postoperative systemic inflammatory response syndrome after colonic surgeries adopted nowadays. Therefore, it is of interest to investigate safety and efficacy of administrating short term intravenous (IV) N acetyl cysteine as add on to l alany l glutamine and total parenteral nutrition on the marker of oxidative stress malondialdehyde and anti- inflammatory marker tumor necrosis factor alpha in patients undergoing colonic surgeries through a prospective, randomized, double blinded, controlled clinical trial
Detailed Description
A prospective, randomized, double blinded, controlled clinical trial will be carried out on 60 patients, who will admit to the critical care unit, Ain Shams hospitals, Cairo, Egypt, following colon surgeries. Before the start of the study, eligible patients were randomized using computer generated list in order to allocate participants to either Group I (n acetyl cysteine group) or Group II (control group) in an equal manner No medication will take before the surgery and only oral fluids were allowed on the day before the operation. All eligible patients underwent bowel preparation with oral 1.745 g/ 30 ml magnesium citrate, and phosphate containing enema on the day before surgery. All patients received the general anesthesia with endotracheal intubation and muscle relaxant.
Data management and analysis were performed using the Statistical Package for Social Sciences (SPSS) software for Windows version 18
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Systemic Inflammatory Response Syndrome
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
60 (Actual)
8. Arms, Groups, and Interventions
Arm Title
N acetylcysteine group
Arm Type
Active Comparator
Arm Description
N Acetyl L Cysteine IV bolus (100 mg/kg dissolved in dextrose5%) infused over 15 minutes, followed by continuous infusion of 50mg/kg/day dissolved in dextrose 5% starting 1hr before induction of anesthesia, and continued for 48 hours after operation
Arm Title
placebo group
Arm Type
Placebo Comparator
Arm Description
received equal volume of dextrose 5% administrated at the same rate and duration as in the study group as a placebo
Intervention Type
Drug
Intervention Name(s)
N Acetyl L Cysteine
Intervention Description
100 mg/kg n acetyl cysteine dissolved in dextrose5%
Intervention Type
Other
Intervention Name(s)
dextrose 5%
Primary Outcome Measure Information:
Title
assessing a change in the level of tumor necrosis factor alpha (TNF alpha) as ant-inflammatory marker reflecting n acetyl cysteine efficacy
Description
TNF alpha was measured using ELISA technique
Time Frame
Venous blood samples were obtained before surgery (baseline evaluation), and on day two after surgery for measuring changes in TNF ALPHA
Title
assessing a change in the level of malondialdehyde as antioxidant marker in the venous blood sample reflecting n acetyl cysteine efficacy
Description
malondialdehyde was measured using colorimetric method for assay
Time Frame
Venous blood samples were obtained before surgery (baseline evaluation), and on day two after surgery for measuring changes in malondialdehyde level
Secondary Outcome Measure Information:
Title
measuring safety of N acetyl cysteine (adverse effects)
Description
recording any adverse effects that may appear
Time Frame
from the beginning of the study till the patient is discharged from the hospital(up to one week)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
need for ICU admission after colonic surgery
requirement of total parenteral nutrition for at least 5 days due to failure of or contraindication for enteral nutrition
signing a written informed consent.
Exclusion Criteria:
patients with persistent hemodynamic instability (systolic blood pressure <80 mm Hg), renal impairment, hepatic insufficiency, severe or uncontrolled sepsis, persistent metabolic acidosis, head trauma,and heart failure
any sensitivity to components of L-alanyl L-glutamine (Dipeptiven®, Fresenius Kabi, Germany) or N acetyl cysteine
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
manal elhammsy, prof
Organizational Affiliation
Ain Shams University , faculty of pharmacy
Official's Role
Study Director
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
All the individual participant data will be stored on the computer and will be available on request only
IPD Sharing Time Frame
it will be available once the trial ends, and for 3 months after publication
IPD Sharing Access Criteria
data will be available on request
Citations:
PubMed Identifier
31381364
Citation
Hamamsy ME, Bondok R, Shaheen S, Eladly GH. Safety and efficacy of adding intravenous N-acetylcysteine to parenteral L-alanyl-L-glutamine in hospitalized patients undergoing surgery of the colon: a randomized controlled trial. Ann Saudi Med. 2019 Jul-Aug;39(4):251-257. doi: 10.5144/0256-4947.2019.251. Epub 2019 Aug 5.
Results Reference
derived
Learn more about this trial
Safety and Efficacy of Adding Intravenous N-acetyl Cysteine in Colon Surgeries
We'll reach out to this number within 24 hrs